Literature DB >> 7341603

Malignant hyperthermia in a halothane-anesthetized horse.

E Waldron-Mease, L V Klein, H Rosenberg, M Leitch.   

Abstract

Malignant hyperthermia developed in a 4-year-old Thoroughbred horse following 3 hours and 15 minutes of halothane anesthesia, with supplementary succinylcholine. Clinical signs included fever, sweating, hyperventilation, tachycardia, and decreased blood pressure followed by a rapid increase in blood pressure. Biochemical aberrations included hypocalcemia, hyperkalemia, hyperphosphatemia, myoglobinuria, and high creatine phosphokinase and ornithine carbamyl transferase activities. Treatment consisted initially of surface cooling with cold water, alcohol and ice, IV administration of cooled balanced electrolyte solutions and sodium bicarbonate, and removal from the anesthetic and rebreathing circuit. Oxygen was given by endotracheal insufflation. The rectum was then packed with ice, the horse was moved to a recovery raft and pool, and his body was packed in ice. Xylazine and dantrolene were given during recovery from anesthesia. Following recovery, treatment consisted of administration of balanced electrolyte solutions, calcium borogluconate, potassium penicillin, meperidine, and additional dantrolene. Muscle biopsy demonstrated exaggerated contracture responses to halothane and caffeine, confirming a diagnosis of malignant hyperthermia. The horse was returned to training following a routine postsurgical convalescent period.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7341603

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  4 in total

1.  Preparation of Injectable Dantrolene for Emergency Treatment of Malignant Hyperthermia-like Syndromes.

Authors:  P J O'brien; G W Forsyth
Journal:  Can Vet J       Date:  1983-06       Impact factor: 1.008

2.  Pharmacokinetic evaluation of oral dantrolene in the dog.

Authors:  J L Haraschak; V C Langston; R Wang; C Riggs; C Fellman; M K Ross; C Bulla; K Lunsford; A Mackin; T Archer
Journal:  J Vet Pharmacol Ther       Date:  2013-11-13       Impact factor: 1.786

3.  Erythrocyte osmotic fragility testing and the prediction of canine malignant hyperthermia susceptibility.

Authors:  P H Cribb; E A Olfert; F B Reynolds
Journal:  Can Vet J       Date:  1986-12       Impact factor: 1.008

4.  Canine malignant hyperthermia: diagnosis of susceptibility in a breeding colony.

Authors:  P J O'brien; P H Cribb; R J White; E D Olfert; J E Steiss
Journal:  Can Vet J       Date:  1983-06       Impact factor: 1.008

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.